Sanofi Consumer Healthcare India Limited closed fiscal year 2025 on a strong note, reporting a 47% year-on-year jump in revenue to ₹2,510 million for the fourth quarter, with profit after tax rising 50% to ₹665 million — figures that signal a company firmly back on its growth footing after navigating product recalls that had weighed on its domestic business.
The Mumbai-headquartered consumer health company, listed on both BSE and NSE, also declared a dividend of ₹75 per share for the full year ended December 31, 2025, rewarding shareholders after a year that saw revenues climb 21% to ₹8,784 million and net profit grow 33% to ₹2,401 million.
The quarterly numbers carry particular significance given the context behind them. Domestic sales in Q4 grew 23% year-on-year, a recovery partly driven by the relaunch of previously recalled products — a development that had dented domestic volumes in earlier periods. Export sales, meanwhile, surged approximately 9.3 times over the same quarter last year, though the company acknowledged this was amplified by a low base from the prior year period. For the full year, exports grew 158% on the same low-base rationale, while domestic sales expanded a more measured 7%.
Himanshu Bakshi, Managing Director of Sanofi Consumer Healthcare India, attributed the turnaround to portfolio discipline and sustained brand investment. “This quarter’s performance emphasises the strength of our core portfolio and the disciplined execution of our growth agenda,” he said. “Our domestic business has delivered healthy double-digit growth for two successive quarters, complemented by strong contributions from our export markets.” Bakshi added that the company’s focus going forward would be on “reinforcing brand fundamentals and driving operational excellence to unlock the next phase of sustainable growth,” with a stated commitment to making self-care “more accessible and effective for every consumer.”
The full-year profit improvement — from approximately ₹1,805 million to ₹2,401 million — was attributed to disciplined cost management and a more favourable product mix, suggesting that margin gains were not purely volume-driven. This distinction matters in the Indian consumer healthcare market, where companies often face margin pressure from competitive pricing and distribution costs.
Chairman Amit Jain framed the annual results as validation of a deliberate long-term strategy. “By driving sustained growth, deepening penetration of our portfolio and accelerating digital transformation, we delivered meaningful outcomes for all our stakeholders,” he said, highlighting that the financial performance made it possible to offer shareholders what he described as a “healthy dividend.”
Sanofi Consumer Healthcare India operates in the self-care segment, with a portfolio that spans analgesics, digestive health, and nutritional products — categories that have seen steady demand in India as awareness around preventive and over-the-counter healthcare grows. The company’s ability to post double-digit domestic growth in back-to-back quarters, even as it managed the operational complexity of product relaunches, will be closely watched by analysts tracking the broader Indian consumer health sector.
With recalled products now back on shelves and exports on an upward trajectory, the company enters 2026 with improved operational visibility. Whether the high export growth rates are sustainable beyond the low-base effect remains a key question — but the underlying domestic momentum, backed by brand investment and margin discipline, points to a business consolidating its recovery rather than simply riding a statistical rebound.
